2-29223363-C-T
Variant summary
Our verdict is Likely benign. The variant received -4 ACMG points: 1P and 5B. PP3BP6BS2
The NM_004304.5(ALK):c.3338G>A(p.Arg1113Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000366 in 1,614,042 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1113W) has been classified as Uncertain significance.
Frequency
Consequence
NM_004304.5 missense
Scores
Clinical Significance
Conservation
Publications
- neuroblastoma, susceptibility to, 3Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -4 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| ALK | ENST00000389048.8 | c.3338G>A | p.Arg1113Gln | missense_variant | Exon 20 of 29 | 1 | NM_004304.5 | ENSP00000373700.3 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152196Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000518 AC: 13AN: 251174 AF XY: 0.0000516 show subpopulations
GnomAD4 exome AF: 0.0000349 AC: 51AN: 1461846Hom.: 0 Cov.: 34 AF XY: 0.0000468 AC XY: 34AN XY: 727224 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000526 AC: 8AN: 152196Hom.: 0 Cov.: 33 AF XY: 0.0000672 AC XY: 5AN XY: 74350 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Uncertain:2
The ALK p.R1113Q variant was not identified in the literature but was identified in dbSNP (ID: rs199987354) and ClinVar (classified as uncertain significance by Ambry Genetics and as likely benign by Invitae). The variant was identified in control databases in 14 of 282560 chromosomes at a frequency of 0.00004955, and was observed at the highest frequency in the Ashkenazi Jewish population in 11 of 10368 chromosomes (freq: 0.001061) (Genome Aggregation Database March 6, 2019, v2.1.1). The p.R1113 residue is conserved in mammals and more distantly related organisms, and computational analyses (MUT Assesor, PolyPhen-2, SIFT, MutationTaster, Revel, FATHMM, MetaLR, DANN) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (Splice AI exome) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. -
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Neuroblastoma, susceptibility to, 3 Uncertain:1Benign:1
- -
- -
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
The p.R1113Q variant (also known as c.3338G>A), located in coding exon 20 of the ALK gene, results from a G to A substitution at nucleotide position 3338. The arginine at codon 1113 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at